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The members of the protein inhibitor of activated STAT (PIAS) family of proteins are implicated in fundamental
cellular processes, including transcriptional regulation, either through action as E3 SUMO ligases or through
SUMO-independent effects. We report here the identification of FIP200 (focal adhesion kinase family-interacting
protein of 200 kDa) as a new PIASy-interacting protein. We show that the interaction depends on the integrity of
the RING finger of PIASy and the carboxy terminus of FIP200. Both in vitro and in vivo sumoylation assays failed
to reveal any sumoylation of FIP200, suggesting that FIP200 is not a bona fide SUMO substrate. Immunofluores-
cence microscopy and subcellular fractionation, either upon forced PIASy expression or in the absence of PIASy,
revealed that interaction with PIASy redistributes FIP200 from the cytoplasm to the nucleus, correlating with
abrogation of FIP200 regulation of TSC/S6K signaling. Conversely, FIP200 enhances the transcriptional activation
of the p21 promoter by PIASy whereas PIASy transcription activity is severely reduced upon FIP200 depletion by
RNA interference. Chromatin immunoprecipitation analysis demonstrates that endogenous PIASy and FIP200 are
corecruited to the p21 promoter. Altogether, these results provide the first evidence for the existence of a close—spatially
controlled—mode of regulation of FIP200 and PIASy nucleocytoplasmic functions.
Protein inhibitors of activated STAT (PIAS) proteins were
originally identified as repressors of the cytokine-induced
STAT transcription factors (7). They have since been shown
also to function as E3 SUMO ligases (18, 39). PIAS proteins
have been found to regulate the functions of many different
proteins, but a major process in which most of these proteins
are involved is gene transcriptional regulation (33, 38). PIAS
proteins may activate or repress transcription, with the precise
mechanism of action depending on the target gene or inter-
acting transcriptional regulator (12, 36). PIAS proteins display
conservation throughout evolution, from yeast to humans.
With the exception of a variable C-terminal region, PIAS pro-
teins are highly similar, with an overall identity of about 50%
at the amino acid level. At the N terminus, PIAS proteins
contain a SAP domain which is thought to target proteins to
AT-rich chromosomal regions known as scaffold or matrix at-
tachment regions (30). PIAS proteins also contain a cysteine/
histidine-rich domain known as the MIZ-zinc finger or SP-
RING domain. This RING finger-like domain plays a key role
in the E3 ligase function of these proteins, favoring the cova-
lent modification of various target proteins by SUMO (38).
Sumoylation is a three-step process similar to ubiquitination
that involves an E1-activating enzyme (Aos1/Uba2 het-
erodimer), an E2-conjugating enzyme (Ubc9), and E3 ligases,
including the Ran-binding protein-2, Polycomb-2, and PIAS
proteins (15, 17, 35). Sumoylation has been shown to regulate
each of its targets in a specific way by altering its conformation,
stability, or interaction and localization properties. While
PIAS proteins may act as E3 SUMO ligases, modulating the
function of the target protein by adding SUMO tags, a growing
body of evidence indicates a SUMO-independent role for
PIAS proteins in their protein partner functions (36). The
human PIAS protein family has at least five members: PIAS1,
PIAS3, the  and  splice variants of PIASx, and PIASy (33).
PIAS1/ mice show increased protection against pathogenic
infection (25), and PIASx/ animals exhibit testis defects
(31), whereas PIASy-deficient mice have modest defects in
interferon and Wnt signaling (28, 42). We recently showed that
overexpression of PIASy in human primary fibroblasts leads to
activation of the Rb and p53 pathways, thus provoking a cel-
lular senescence arrest (2). PIASy promotes p53 sumoylation
and transcriptional activation of p53 downstream target genes
involved in senescence such as the gene for p21. Accordingly,
PIASy/ murine embryo fibroblasts (MEFs) show an in-
creased resistance to senescence which is accompanied by a
lack of p21 up-regulation.
FIP200 (focal adhesion kinase family-interacting protein of
200 kDa) has been involved in fundamental cellular processes
including cell size, migration, survival, and cell cycle progres-
sion through interaction with multiple signaling pathways (9).
It was first identified in yeast two-hybrid screens in which this
protein was found to interact with and inhibit the kinase ac-
tivities of Pyk2 and FAK (1, 40). It is characterized by a large
coiled-coil region containing a leucine zipper motif. More re-
cent studies have described a role for FIP200 in cell cycle
regulation mainly via p53 stabilization and cyclin D1 degrada-
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tion (26). It has been further shown that FIP200 interacts with
and inhibits the tuberous sclerosis complex (TSC) function,
correlating with its ability to activate S6 kinase (S6K) phos-
phorylation and increase cell size (6, 10). Inactivation of the
gene for FIP200 in mice leads to embryonic lethality, associated
with defective heart and liver development. At the cellular level,
FIP200/ MEFs and liver cells show increased apoptosis to-
gether with alteration of the tumor necrosis factor alpha-JNK and
TSC/mTOR pathways (11). Chano et al. (3) independently
identified the FIP200 protein, which they called RB1-inducible
coiled-coil 1 (RB1CC1), as an inducer of RB1 expression in
human leukemia cells. Moreover, the gene for FIP200 is fre-
quently deleted in breast cancer, suggesting a potential tumor
suppressor role for FIP200 (5).
To better understand the molecular mechanisms by which
PIASy regulates cellular functions, we used a biochemical pu-
rification approach to identify cellular proteins that interact
with PIASy. Here, we report the identification of PIASy inter-
action with FIP200 both in vitro and in vivo. We show that this
interaction is important for the nucleocytoplasmic partitioning
of FIP200. PIASy-induced accumulation of FIP200 in the nu-
cleus impairs the cytoplasmic activity of FIP200 on TSC bind-
ing and S6K phosphorylation, thus highlighting an as-yet-un-
appreciated role for PIASy in the regulation of the nuclear
shuttling of other proteins to modulate their activities. Con-
versely, nuclear PIASy and FIP200, which co-occupy the p21
promoter, combine their effects to increase the promoter’s
activity. Finally, we failed to detect any sumoylation of FIP200
in our experimental conditions, suggesting that the functional
interaction between PIASy and FIP200 is not coupled, at least
directly, to any SUMO ligase action of PIASy on FIP200.
MATERIALS AND METHODS
Plasmids, cell culture, and infection. Flag/HA-PIASy, HA-PIASy, Flag/HA-
PIASx, and HA-FIP200 were inserted into pcDNA3 (Invitrogen) by standard
procedures. The N terminus of FIP200 (amino acids [aa] 1 to 633) and the C
terminus of FIP200 (aa 634 to 1591) were inserted into pcDNA3 and pFlag-
CMV-6A (Sigma) or His-pcDNA3, respectively. pcDNA3-HDAC1, Flag/HA-
PIASy mut (PIASy-C342F), pBABE-HA-PIASy, Myc-TSC1, GST-TSC2, and
HA-S6K were as previously described (2, 10, 20). Flag-FIP200 was kindly pro-
vided by T. Chano, pRC-p53 and p21-luciferase reporter by M. Oren, the PIAS1
and PIAS3 plasmids by K. Shuai, and T7-PIASy by J. Seeler.
HeLa, U2OS, HEK293, and HEK293T cells were grown in Dulbecco modified
Eagle medium supplemented with 10% fetal bovine serum, 100 U/ml penicillin,
and 100 g/ml streptomycin. All cells were maintained at 37°C under an atmo-
sphere containing 5% CO2. FIP200/ and FIP200/ MEFs (11), as well as
PIASy/ and PIASy/ MEFs (28), were isolated from embryonic day 12.5
embryos and cultured under the same conditions. Infection of MEFs by retro-
virus-mediated gene transfer was performed as described previously (2).
Transfection, siRNA, and reporter gene assay. Cells were transfected with 0.3
g p21-luciferase and 0.01 g pCMV--gal reporters plus expression constructs
by using Lipofectamine and Plus transfection reagents (Invitrogen) according to
the manufacturers’ instructions. -Galactosidase and luciferase activities were
measured with the Galacto-Star (Tropix) and Luciferase Assay Systems (Pro-
mega) kits according to the manufacturers’ instructions. Luciferase activities
were normalized to -galactosidase activities. For small interfering RNA
(siRNA) knockdown experiments, U2OS cells grown in six-well plates were
transfected with 100 nmol duplex oligonucleotide with Oligofectamine reagent
(Invitrogen) in accordance with the manufacturer’s instructions. Two indepen-
dent duplex FIP200 siRNA sequences, (i) 5-GGAGAUUUGGUACUCAUCA
UCA-3 and 5-AGCUUGAUGAUGAGUACCAAAUCUCC-3 (10) and (ii)
5-GGAGUGGGCUGGUGCUUUAUU-3 and 5-UAAAGCACCAGCCCA
CUCCUU-3, were used. A scrambled siRNA sequence (Dharmacon) was used
as a negative control. On the next day, the cells were transfected with PIASy and
p21 reporter constructs as described above. The cells were incubated for 3 days
and then lysed for the monitoring of luciferase activity and Western blotting.
To detect S6K phosphorylation, HEK293T cells grown in 10-cm dishes were
cotransfected with vectors encoding HA-S6K, T7-PIASy, and HA-FIP200. After
2 days, growing cells were directly lysed in Laemmli buffer for Western blotting.
Antibodies. We generated an anti-FIP200 polyclonal rabbit antiserum (Ab244)
directed against a glutathione S-transferase (GST) fusion protein encompassing
C-terminal aa 1350 to 1591 of human FIP200. We used the following antibodies:
rat anti-PIASy monoclonal antibody recognizing mouse PIASy (28), rabbit poly-
clonal anti-PIASy antibody recognizing human PIASy, and rabbit polyclonal
anti-SUMO antibody mainly recognizing human SUMO-1 (2), as well as anti-
bodies against vinculin (Santa Cruz), PARP-1 (Santa Cruz), green fluorescent
protein (GFP; Santa Cruz), Flag (Sigma), hemagglutinin (HA; Covance), T7
(Novagen), Myc (Santa Cruz), GST (Santa Cruz), p53 (Santa Cruz), tubulin
(Oncogene), -actin (Sigma), SUMO-2/3 (Abgent), and Thr389 phospho-S6K
(Cell Technology Inc.).
ChIP. U2OS cells were cross-linked by incubation for 10 min at 20°C with
formaldehyde (added directly to the culture medium at a final concentration of
1%), and chromatin immunoprecipitation (ChIP) was carried out as previously
described (2). For ChIP, we used antibodies against PIASy, FIP200, p53, and
GFP. DNA obtained by ChIP was amplified by PCR in a reaction mixture
containing each primer pair at 10 M. The following primers were used: for the
p21 promoter, 5-CACCACTGAGCCTTCCTCAC-3 and 5-CTGACTCCCAG
CACACACTC-3 (32); for the GADD45 promoter, 5-GGATCTGTGGTAG
GTGAGGGTCAGG-3 and 5-GGAATTAGTCACGGGAGGCAGTGCA
G-3 (34); for the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene,
5-GTATTCCCCCAGGTTTACAT-3 and 5-GGAGTGAGTGGAAGACAG
AA-3 (19).
Preparation of nuclear and cytoplasmic protein fractions. Phosphate-buffered
saline-washed cell pellets were resuspended in 10 volumes of buffer 1 (0.5 M
sucrose, 15 mM Tris [pH 7.5], 60 mM KCl, 0.25 mM EDTA, 0.125 mM EGTA,
1 Boehringer protease tablet/5 ml). The cells were then allowed to recover for 5
min at 4°C, 10% NP-40 was added dropwise, and lysis was monitored under a
light microscope. The reaction was stopped by adding NP-40 when the nuclei
were free of cytoplasmic contaminants. The lysed cells were centrifuged at 1,000 
g. The supernatant (cytoplasmic fraction) was decanted, and the pellet (corre-
sponding to the nuclei) was resuspended in extraction buffer (20 mM Tris-Cl [pH
8.5], 10% glycerol, 2 mM dithiothreitol, 0.8 M KCl). The DNA was sheared by
passage through a 25-gauge syringe and incubated for 45 min on ice. The mixture
was centrifuged at 21,000  g, and the nuclear fraction was dialyzed against 150
mM KCl in extraction buffer. The various cellular fractions were analyzed by
immunoblotting.
GST pull-down and in vitro sumoylation assay. GST, GST-PIASy, and GST-
FIP200(1350-1591) were produced in BL21DE3 E. coli cells and purified accord-
ing to standard procedures. GST pull-down assays were carried out as previously
described (2). In vitro sumoylation assays were carried out with in vitro-trans-
lated and radiolabeled HDAC1 and FIP200 and recombinant E1 (Aos1/Uba2)
(370 nM), E2 (Ubc9) (630 nM), and SUMO-1 (7 M) in 30 mM Tris–5 mM
ATP–10 mM MgCl2 (pH 7.5) at 30°C as previously described (20). Recombinant
GST-PIASy was added at a final concentration of 500 nM.
Immunoprecipitation, immunoblotting, and immunofluorescence. Cells were
lysed by adding an equal volume of 1 CHRIS buffer (50 mM Tris [pH 8.0],
0.5% Nonidet P-40, 200 mM NaCl, 0.1 mM EDTA, 1 Boehringer protease
tablet/5 ml). Specific polypeptides were then recovered by immunoprecipitation
from equivalent amounts of cellular proteins. Immune complexes were collected
by incubation with protein A/G (Oncogene). The immunoprecipitates were
washed three times in lysis buffer, and the proteins were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The protein
bands were then immunoblotted according to the standard procedure.
Cells were immunolabeled with a primary antibody (against FIP200 or HA)
and a secondary antibody (Sigma) as previously described (2). The cells were
then examined with a Leica DMIRB microscope.
PIASy complex purification and mass spectrometry. HEK293T cells were
stably transfected with Flag/HA-PIASy or with an empty vector as the control.
Cell lysates from 300 flasks (150-cm2 flasks) were used for Flag immunoprecipi-
tation, followed by Flag-peptide elution under the conditions described above.
The bands visible on SDS-PAGE were digested with trypsin within the gel and
extracted as described by Shevchenko et al. (37). The extracted peptides were
analyzed in a liquid chromatography-coupled electrospray ionization quadrupole
time-of-flight mass spectrometer (Q-ToF Ultima; Waters) under standard con-
ditions. Proteins were identified by using the fragment spectra of sequenced
peptides for searches against the NCBI nr database by using Mascot as the search
engine.
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Identification of PIASy interaction with FIP200. To better
characterize the cellular function of PIASy, we used a purifi-
cation approach to identify proteins interacting with PIASy.
We established a stable human embryonic kidney simian virus
40 large T antigen (HEK293T) cell line expressing a Flag/HA-
tagged version of the E3 SUMO ligase PIASy and a HEK293T
control cell line carrying the empty vector. Lysates were
prepared from both stably transfected lines, incubated with
anti-Flag–agarose, and subjected to Flag-peptide elution. The
protein profiles of the eluted fractions were analyzed by SDS-
PAGE and silver staining. Flag affinity purification gave about
30 visible protein bands in the PIASy-expressing cell line, 4 of
which were not visible in the control cell line (Fig. 1). Among
those, two major ones, corresponding to molecular masses of
60 kDa and 200 kDa, were further identified by mass spec-
trometry as PIASy and FIP200, respectively. A yeast-two-hy-
brid screen performed in parallel with PIASy as bait identified
FIP200 as a major PIASy-interacting partner (9 independent
FIP200 clones out of 69 interacting clones) (J. Seeler and A.
Dejean, unpublished results). These results indicate that
PIASy associates with FIP200 in eukaryotic cells.
The interaction of PIASy and FIP200 was tested next by
coimmunoprecipitation. Flag-FIP200 was cotransfected with
either Flag/HA-PIASy or empty Flag/HA-vector in HEK293T
cells. Cell lysates were immunoprecipitated with HA antibody,
followed by Western blotting with Flag antibodies. As shown in
Fig. 2A, Flag/HA-PIASy, but not the empty Flag/HA-vector,
efficiently immunoprecipitated Flag-FIP200 (lanes 4 and 5).
Interestingly, a PIASy protein (Flag/HA-PIASy mut) with a
RING finger mutation that causes a defect in SUMO ligase
activity due to the replacement of Cys 342 with Phe but does
not affect the structure of E3 (2) failed to associate with Flag-
FIP200 (lane 6). This suggests that an intact RING finger
structure and, by extension, the E3 ligase activity of PIASy are
required for interaction with FIP200. By contrast, deletion of
the SAP domain of PIASy had no effect on the PIASy-FIP200
interaction (data not shown). Further experiments with full-
length FIP200 or deletion mutant forms containing either the
N-terminal (aa 1 to 633) or the C-terminal (aa 634 to 1591)
domain revealed that the C-terminal domain of FIP200 medi-
ates the association with PIASy (Fig. 2B). To evaluate the
interaction at the level of endogenous proteins, we generated
a polyclonal antibody against the C-terminal domain of FIP200
(Ab244). As shown in Fig. 2C, endogenous FIP200 protein
immunoprecipitated a significant amount of endogenous
PIASy whereas a control GFP antibody did not. Conversely, we
detected no FIP200 protein with an antibody directed against
the C terminus of PIASy (data not shown), probably because of
the proximity between the recognition domain of the antibody
and the interacting region. However, we found that ectopically
expressed PIASy immunoprecipitated endogenous FIP200
(Fig. 2D, lane 5). By contrast, overexpression of other mem-
bers of the PIAS family, PIAS1, PIAS3, and PIASx, failed to
reveal any association with endogenous FIP200 (Fig. 2D, lanes
2 to 4), indicating that this interaction is specific to this
member of the PIAS family.
We next carried out a GST pull-down assay with recombi-
nant GST-PIASy and in vitro translated, 35S-labeled, full-
length FIP200. FIP200 bound GST-PIASy with the same effi-
ciency as HDAC1, which was used as a positive control (2, 8),
but not GST alone (Fig. 2E). Consistent with the coimmuno-
precipitation experiments (Fig. 2B), GST-PIASy efficiently
pulled down the C-terminal domain of 35S-labeled FIP200 but
not its N-terminal domain (Fig. 2E). In a reciprocal experi-
ment, 35S-labeled PIASy bound a fusion protein containing the
extreme C terminus of FIP200 (aa 1350 to 1591) (Fig. 2F).
These data suggest a direct interaction between PIASy and
FIP200.
Together, these results identify FIP200 as a PIASy-interact-
ing protein and suggest that the RING finger of PIASy and the
FIP200 1350-to-1591-aa region are required for their interac-
tion.
PIASy regulates the subcellular localization of FIP200. To
better characterize the interaction between PIASy and FIP200
at the subcellular level, we carried out immunofluorescence
studies with HeLa cells transfected with expression vectors for
Flag-FIP200 together with HA-PIASy, HA-PIASy mut, HA-
PIASx, or a control vector (Fig. 3A). Consistent with previous
findings (24, 40), FIP200 showed a predominantly diffuse cy-
toplasmic localization (Fig. 3A, parts A to D) while, in con-
trast, PIASy presented almost exclusively nuclear staining
(data not shown). Coexpression of FIP200 and PIASy induced
a drastic shift of the subcellular location of FIP200 from the
cytoplasm to the nucleus together with PIASy (Fig. 3A, parts E
FIG. 1. Identification of FIP200 as a PIASy-associated protein
by mass spectrometry. Lysates of HEK293T cells expressing Flag/
HA-PIASy (PIASy) were immunoprecipitated with Flag antibody
affinity resins. HEK293T cells transfected with empty Flag/HA-
vector were used as a control (Ctrl). Immunoprecipitates were
resolved by SDS-PAGE in a 10% polyacrylamide gel and silver
staining. The four bands specifically present in the PIASy-express-
ing cells are marked by stars. The PIASy and FIP200 polypeptides
identified by mass spectrometry analyses are indicated. Molecular
masses are indicated on the left.
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to H). By contrast, overexpression of either SUMO ligase-
inactive PIASy (PIASy mut) or the other PIAS family member
PIASx, both of which failed to associate with FIP200 in in-
teraction studies (Fig. 2A and D), did not induce nuclear
accumulation of FIP200.
As all attempts to detect endogenous FIP200 protein by
immunofluorescence failed, we investigated the subcellular
distribution of endogenous FIP200 protein by biochemical
fractionation of HEK293T cell lysates, followed by Western
blotting. Endogenous FIP200 was found to be present in
roughly similar amounts in the nuclear and cytoplasmic frac-
tions (Fig. 3B, lanes 3 and 4), a situation slightly different from
the mostly cytoplasmic distribution of ectopically expressed
FIP200 in HeLa cells as revealed by immunofluorescence (Fig.
3A). Upon overexpression of HA-PIASy, which was, as ex-
pected, found mostly in the nucleus, the levels of endogenous
FIP200 in the nuclear fraction increased substantially (Fig. 3B,
lane 2), whereas the amount of cytoplasmic FIP200 decreased
accordingly (Fig. 3B, lane 1).
In order to confirm these results in a more physiological
situation, we studied the subcellular localization of endog-
enous FIP200 in PIASy/ and PIASy/ MEFs by using
FIG. 2. FIP200 interacts with PIASy in vivo. (A) HEK293T cells were transfected with a combination of empty Flag/HA-vector (Ctrl), wild-type
(wt) Flag/HA-PIASy, C342F mutant (mut) Flag/HA-PIASy, and Flag-FIP200 as indicated. At 24 h after transfection, 100 g of whole cell lysate
(WCL) (lower part) or cell lysates immunoprecipitated with HA-conjugated agarose (upper part) were subjected to SDS-PAGE followed by
Western blotting with an anti-Flag antibody. (B) HEK293T cells were transfected with T7-PIASy together with empty HA-vector (Ctrl), full-length
HA-FIP200 (FL), or the HA-FIP200 N terminus (NT). Whole cell lysate was analyzed directly by Western blotting (WB) with an anti-HA or
anti-T7 antibody or after immunoprecipitation (IP) with T7-conjugated agarose (left side). HEK293T cells were transfected with T7-PIASy
together with empty Flag-vector (Ctrl), full-length (FL) Flag-FIP200, or the Flag-FIP200 C terminus (CT). Whole cell lysate was analyzed directly
by Western blotting with anti-Flag or anti-T7 antibody or after immunoprecipitation with T7-conjugated agarose (right side). Molecular masses
are indicated. In the schematic diagram of the human FIP200 protein at the bottom, full-length FIP200, the N-terminal domain of FIP200, the
C-terminal domain of FIP200, and the corresponding amino acids are indicated; the FIP200 coiled-coiled domain (CC) is also indicated.
(C) Lysates of HEK293T cells were subjected to immunoprecipitation with anti-FIP200 antibody and with anti-GFP antibody as a control. Whole
cell lysate or precipitates were Western blotted with antibodies against FIP200 and PIASy. (D) HEK293T cells were transfected with empty
Flag-vector, Flag-PIAS1, Flag-PIAS3, Flag/HA-PIASx, and Flag/HA-PIASy. At 24 h after transfection, 100 g of whole cell lysate (bottom) or
immunoprecipitated anti-Flag antibody (top) was subjected to SDS-PAGE, followed by detection with anti-Flag antibody or anti-FIP200 antibody.
(E) GST and GST-PIASy immobilized on glutathione beads were incubated with the in vitro-translated, 35S-labeled full length (FL), N terminus
(NT), or C terminus (CT) of FIP200; 35S-labeled HDAC1 (positive control); or 35S-labeled luciferase (negative control). Bound complexes were
analyzed by autoradiography. Recombinant GST and GST-PIASy were detected by Coomassie staining. (F) GST and GST-FIP200 aa 1350 to 1591
immobilized on glutathione beads were incubated with in vitro-translated 35S-labeled PIASy or 35S-labeled luciferase. Bound complexes were
analyzed by autoradiography. Recombinant GST and GST-FIP200 were detected by Coomassie staining.
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the biochemical fractionation approach. In PIASy/
MEFs, endogenous PIASy was predominantly found in the
nuclear fraction whereas a small amount could be detected
in the cytoplasmic fraction (Fig. 3C, lanes 1 and 2). Endog-
enous FIP200 was found in both the nuclear and cytoplasmic
fractions in roughly similar amounts (Fig. 3C, lanes 1 and 2).
Interestingly, in PIASy/ MEFs, the amount of nuclear
FIP200 was severely reduced and FIP200 was found almost
exclusively in the cytosol (Fig. 3C, lanes 3 and 4). Further-
more, reexpression of PIASy in PIASy/ MEFs restored an
equal distribution of FIP200 in the nuclear and cytoplasmic
fractions (Fig. 3C, lanes 5 and 6), similar to what observed
in PIASy/ MEFs, indicating that PIASy is directly respon-
sible for the observed change in FIP200 nuclear expression.
Together, these data indicate that PIASy regulates the nu-
clear versus cytoplasmic pools of FIP200.
PIASy interferes with FIP200 regulation of the TSC/S6K
pathway. To assess whether the shift in FIP200 subcellular
localization upon the expression of PIASy may have an impact
on FIP200 function, we studied the effect of PIASy on FIP200-
FIG. 3. PIASy regulates the nuclear-to-cytoplasmic ratio of FIP200. (A) HeLa cells grown on coverslips were transfected with expression vector
for Flag-FIP200 together with empty HA-vector (Ctrl, A to D) or vector encoding HA-PIASy (E to H), HA-PIASy mut (I to L), or HA-PIASx
(M to P). At 24 h after transfection, cells were fixed with paraformaldehyde and stained with anti-FIP200 antibody–fluorescein-conjugated antibody
(green), anti-HA antibody–Texas Red-coupled antibody (red), or Hoechst dye (blue). Merged image overlays were obtained with Meta software.
Additional image processing was carried out with Canvas software. (B) HEK293T cells were transfected with empty Flag/HA-vector (Ctrl) or
Flag/HA-PIASy vector. At 24 h later, cells were processed for nuclear (N)/cytoplasmic (C) fractionation as described in Materials and Methods.
A 100-g sample of each fraction was resolved by SDS-PAGE and analyzed by Western blotting (WB) with antibodies against FIP200, HA
(PIASy), vinculin as the cytoplasmic marker, and poly(ADP-ribose) polymerase 1 (PARP1) as the nuclear marker. (C) PIASy/ or PIASy/
MEFs were retrovirally infected with empty pBABE vector (Ctrl) or pBABE-HA-hPIASy vector and selected for 2 days with puromycin (4 mg/ml).
The distribution of endogenous FIP200 and endogenous or exogenous PIASy in the nuclear (N) and cytoplasmic (C) protein fractions was analyzed
by Western blotting with anti-FIP200 antibody and rat anti-PIASy monoclonal antibody recognizing mouse and human PIASy (28). The quality
of fractionation was verified as for panel B.
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regulated TSC/S6K signaling. Indeed, recent studies have
shown that FIP200 associates with both TSC1 and TSC2 and
functions as an activator of the mammalian target of rapamycin
(mTOR) pathway—possibly through disruption of TSC1-TSC2
complex formation—thus correlating with its ability to increase
cell size and stimulate S6K phosphorylation (6, 10, 11). We first
examined the possible effect of PIASy on FIP200 interaction
with the TSC1 and TSC2 proteins. HEK293T cells were co-
transfected with vectors expressing Myc-TSC1 and HA-FIP200
in the absence or presence of T7-PIASy. As expected, TSC1
efficiently immunoprecipitated FIP200. Interestingly, overex-
pression of PIASy significantly reduced the association be-
tween TSC1 and FIP200 (Fig. 4A). Similar experiments sub-
stituting GST-TSC2 for Myc-TSC1 showed that overexpression
of PIASy almost entirely abrogated the TSC2-FIP200 interac-
tion (Fig. 4B). These data indicate that PIASy negatively reg-
ulates TSC1/TSC2-FIP200 complex formation. No association
between PIASy and TSC1 or TSC2 could be detected under
these experimental conditions (Fig. 4A and B), suggesting that
PIASy does not compete with FIP200 for TSC binding. To go
further, we tested whether PIASy may affect FIP200-induced
activation of S6K. HEK293T cells were cotransfected with
HA-S6K vector or pcDNA3 empty vector along with plasmids
encoding HA-FIP200 and/or T7-PIASy. Cell lysates were an-
alyzed by Western blotting with an anti-Thr389 phosphorylated
S6K antibody to determine its activation state or anti-HA and
anti-T7 antibodies to verify the expression levels of the pro-
teins. Consistent with previous findings (10), overexpression of
FIG. 4. PIASy inhibits FIP200-induced activation of the mTOR pathway. (A) HEK293T cells were transfected with a combination of
Myc-TSC1, HA-FIP200, T7-PIASy, and empty vector as indicated. Whole cell lysates (WCL) or Myc immunoprecipitates (IP) were subjected to
SDS-PAGE and analyzed by Western blotting (WB) with antibodies against HA, Myc, or T7. (B) HEK293T cells were transfected with a
combination of GST-TSC2, HA-FIP200, T7-PIASy, and empty vector as indicated. Cell lysates were prepared and incubated with glutathione
beads. Bound proteins were eluted, subjected to SDS-PAGE, and analyzed by Western blotting with antibodies against HA, GST, or T7. (C) PIASy
abrogates FIP200-dependent S6K phosphorylation. HEK293T cells were cotransfected with vectors encoding HA-S6K, HA-FIP200, and T7-PIASy
or the corresponding empty vectors. At 48 h later, cells were directly lysed in Laemmli buffer and lysates were analyzed by Western blotting. S6K
phosphorylation was detected with an antibody directed against Thr389 phospho-S6K, and the expression levels of S6K, FIP200, and PIASy were
verified with anti-HA or anti-T7 antibodies. IgG, immunoglobulin G.
2776 MARTIN ET AL. MOL. CELL. BIOL.
 o
n
 February 22, 2016 by M










FIP200 alone increased S6K phosphorylation (Fig. 4C, com-
pare lanes 2 and 4). Cotransfection of PIASy with FIP200
returned S6K phosphorylation to its basal level (Fig. 4C, com-
pare lanes 5 and 4). Interestingly, we observed a slight decrease
in S6K phosphorylation when we overexpressed PIASy alone
(Fig. 4C, compare lanes 3 and 2), an observation which most
likely reflects the depletion of endogenous cytosolic FIP200 by
PIASy (Fig. 3B).
Taken together, these data show that PIASy impairs the
association of FIP200 with TSC1/TSC2 and abrogates FIP200-
dependent S6K phosphorylation, correlating with its ability to
redistribute FIP200 from the cytoplasm to the nucleus.
FIP200 and SUMO modification. Modification by SUMO
has been shown to have an impact on many biological pro-
cesses, including protein-protein interaction responsible for
subcellular relocalization (15, 17, 35). Considering that PIASy
functions as an E3 SUMO ligase, we investigated whether the
interaction of FIP200 with PIASy resulted in its sumoylation,
possibly accounting for its nuclear translocation. We carried
out an in vitro sumoylation experiment with in vitro-translated,
35S-labeled FIP200 or 35S-labeled HDAC1, a bona fide SUMO
substrate for PIASy used as a positive control (2, 8), to which
we added or did not add recombinant PIASy. The presence of
SUMO-1 in the reaction mixture did not induce the forma-
tion of higher-molecular-weight species of FIP200, a situa-
tion that remained unchanged even after the addition of
PIASy (Fig. 5A, lanes 5 and 6). Under the same conditions,
PIASy enhanced the formation of HDAC1–SUMO-1 con-
jugates, which were readily detectable in the presence of
SUMO-1 (Fig. 5A, lanes 2 and 3). Studies performed in vivo
similarly failed to reveal any sumoylation of FIP200 when
overexpressed in HeLa cells, even upon the forced expres-
sion of SUMO-1 and/or PIASy (Fig. 5B, left side). By con-
trast, LEF-1, a well-known PIASy SUMO target (30), un-
derwent efficient sumoylation in a parallel assay (Fig. 5B,
right side). Thus, FIP200 does not appear to be a bona fide
substrate for SUMO under either our in vitro or in vivo
experimental conditions, suggesting that the effects of PIASy on
FIP200 localization and function do not rely on sumoylation of
FIP200 per se.
Having established that PIASy does not act as a SUMO
ligase for FIP200, we investigated whether FIP200 may rather
FIG. 5. FIP200 and SUMO modification. (A) In vitro-translated 35S-labeled HDAC1 and 35S-labeled FIP200 were incubated with the indicated
recombinant proteins as described in Materials and Methods. Reaction mixtures were analyzed by SDS-PAGE and autoradiography. (B) HeLa
cells were transfected with HA-FIP200 alone or together with SUMO-1 and Flag-PIASy. Whole cell lysates (WCL) were analyzed by Western
blotting (WB) with anti-HA antibody as shown on the left. The same experiment but with HA-LEF1 as the substrate is shown on the right. The
asterisk indicates an aspecific band. (C) FIP200 does not affect p53 sumoylation. HEK293 cells were transfected with empty HA-vector (Ctrl),
HA-FIP200, T7-PIASy, and HA-FIP200 together with T7-PIASy. At 24 h later, cells were treated with 400 ng/ml doxorubicin for 5 h (). Cell
lysates were prepared in 2 Laemmli buffer with 5 mM N-ethylmaleimide and Western blotted with the indicated antibodies. (D) Cell lysates were
prepared in CHRIS buffer with 5 mM N-ethylmaleimide and Western blotted with antibodies against SUMO-1 and SUMO-2/3. Sumoylated
RanGAP1 and free SUMO are indicated.
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act as a cofactor for the E3 activity of PIASy. Both FIP200 and
PIASy associate with p53 (2, 26); in addition, PIASy functions
as an E3 ligase for p53 sumoylation (2). We thus tested the
possibility that FIP200 may affect PIASy-mediated sumoyla-
tion of p53. We overexpressed PIASy, FIP200, or PIASy to-
gether with FIP200 in HEK293 cells treated with doxorubicin,
a DNA-damaging agent that induces sumoylation of endoge-
nous p53 (21). As expected, ectopic expression of PIASy en-
hanced p53 sumoylation (Fig. 5C, lane 3). However, concom-
itant expression of FIP200 did not modify the profile of
SUMO-modified p53 (Fig. 5C, lane 4). FIP200 alone did not
affect the steady-state level of sumoylated p53 either (Fig. 5C,
lane 2). Thus, FIP200 does not seem to behave as a cofactor
with PIASy for p53 sumoylation. We then investigated whether
the general SUMO modification pattern was affected in the
absence of FIP200 by carrying out Western blot analyses of cell
extracts from FIP200/ and FIP200/ MEFs (11) with
SUMO-1 and SUMO-2/3 antibodies (Fig. 5D). The global
modification profiles of SUMO-1 and SUMO-2/3 were similar
in the two cell types, indicating that loss of FIP200 has no
significant effect on overall sumoylation, although it does not
exclude the possibility that FIP200 plays a role in the modifi-
cation of specific substrates.
FIP200 is an important cofactor with PIASy in p21 pro-
moter activation. Expression of PIASy in human fibroblasts
has been shown to induce premature senescence together with
activation of p53 targets such as p21 (2). Other studies have
independently reported that FIP200 can induce p21 expression
in a p53-dependent manner (26). We thus studied the effect of
FIP200 on PIASy-mediated activation of the p21 promoter in
U2OS cells. Consistent with previous findings, expression of
PIASy alone led to robust activation of a p53-responsive p21-
luciferase reporter, whereas under these conditions, FIP200
only slightly stimulated the promoter activity (Fig. 6A, lanes 2
and 3). Activation of the p21 promoter by PIASy and FIP200
was p53 dependent, as deletion of both p53-binding sites within
the p21 promoter abolished this response (data not shown).
Expression of FIP200 together with PIASy led to a modest, yet
reproducible, increase in PIASy-induced p21 promoter activity
in a dose-dependent manner (Fig. 6A, lanes 4 to 6), suggesting
that the interaction between PIASy and FIP200 may be impor-
tant for p21 activation.
To further address this point, we studied the effects of the
down-regulation of endogenous FIP200 protein levels on the
induction of p21 promoter activity by PIASy. Accordingly,
U2OS cells were transfected with two different FIP200 siRNAs
(I and II) or a scrambled siRNA as a negative control together
with FLAG-HA-PIASy and the p21 reporter gene. Normal
FIP200 protein levels were associated with the expected induc-
tion of p21 promoter activity by PIASy (Fig. 6B). In contrast,
depletion of the FIP200 protein with either of the two FIP200-
specific siRNAs almost entirely abolished PIASy-dependent
transcriptional activation of the promoter (Fig. 6B). Control
siRNA had no effect in a similar experiment (data not shown).
These data strongly suggest that FIP200 is required for PIASy-
mediated activation of the p21 promoter.
Next, we investigated whether FIP200 could cooperate with
PIASy to regulate p21 expression through direct binding to the
p21 promoter. To address this question, ChIP experiments
were performed with U2OS cells. Both endogenous PIASy and
FIP200 were found to efficiently bind the p21 promoter in the
same region as p53, which was used as a positive control (Fig.
6C). ChIP assays with GFP antibody were performed as a
negative control and showed only weak background binding.
FIG. 6. Role of FIP200 in the regulation of p21 promoter activity by PIASy. (A) Flag/HA-PIASy (100 ng), HA-FIP200 (100 ng), or
Flag/HA-PIASy (100 ng), together with increasing amounts of HA-FIP200 (100, 250, and 500 ng), was transfected into U2OS cells with a
p21-luciferase reporter (0.3 g) together with a cytomegalovirus–-galactosidase vector for normalization. The expression of these constructs was
checked by Western blotting (WB) with an anti-HA antibody. (B) U2OS cells were transfected with scrambled siRNA (control) or two different
FIP200 siRNAs (I and II) as described in Materials and Methods. At 24 h after this initial transfection, the cells were transfected with empty
Flag/HA-vector () or Flag/HA-PIASy () together with the p21 promoter reporter and the cytomegalovirus–-galactosidase vector for
normalization. The expression of these constructs was checked by Western blotting. The columns show the means of three independent
experiments, and the bars show the standard errors. (C) Endogenous PIASy and FIP200 bind to the p21 and GADD45 promoters. ChIP analysis
of the p21 promoter (top) and the GADD45 promoter (bottom) in U2OS cells. Cells were harvested, and ChIP was carried out with antibodies
against FIP200, PIASy, p53, or GFP. The GAPDH genomic region was used as a negative control. Input, total cross-linked genomic DNA (1 ng).
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No binding to an unrelated genomic fragment of the GAPDH-
encoding gene was detected either. In similar experiments, we
also found occupancy of the p53-responsive GADD45 pro-
moter by endogenous FIP200, PIASy, and p53, indicating that
association of FIP200 and PIASy on p53 targets is not solely
restricted to the p21 promoter (Fig. 6C).
Together, these results indicate that PIASy and FIP200 are
corecruited together with p53 to the p21 promoter to regulate
its activity.
DISCUSSION
PIAS proteins have been shown to have an impact on the
function of many different proteins (12, 33, 36, 38). Originally
identified as negative cytokine regulators (7), they have been
shown also to function as E3 ligases for the SUMO modifica-
tion pathway (18, 39). Evidence is accumulating that PIAS
proteins act as transcriptional coregulators, and one major
mechanism through which PIAS proteins operate appears to
be subcellular relocalization of interacting proteins (15, 17,
35). Recently, we have shown that PIASy, one of the five PIAS
family members, induces cellular senescence in part through
transcriptional activation of p53 downstream targets such as
p21 (2). To gain further insight into the regulatory mechanisms
of PIASy, we searched for PIASy-interacting partners. We
report here the identification of FIP200 as a new PIASy-inter-
acting protein and demonstrate that this interaction is impor-
tant for the subcellular localization and signal transduction
activities of FIP200 such as S6K activation. Conversely, FIP200
functions as a coactivator of PIASy in p21 promoter activation.
Taken together, our results reveal that PIASy and FIP200 act
together to regulate signal transduction and transcriptional
activity and highlight a novel mode of regulation of FIP200
function via its PIASy-dependent nucleocytoplasmic redistri-
bution.
PIASy-FIP200 interaction and sumoylation. Our observa-
tion that a PIASy variant with a mutation in the RING finger
structure fails to interact with FIP200 suggests that the E3
ligase activity of PIASy plays a crucial role in the PIASy-
FIP200 association. Thus, a likely hypothesis was that PIASy
may catalyze FIP200 sumoylation. However, the absence of
detectable SUMO-modified forms of FIP200 both in vitro and
in vivo, even under forced expression of PIASy, does not sup-
port this notion. Moreover, in the SUMO system, most sub-
strates can associate with several members of the PIAS family
which, in turn, stimulate their sumoylation. Further evidence
for this redundancy is provided by the observation that
PIASy/ mice are phenotypically normal (28, 42), suggesting
that other members of this protein family compensate for the
lack of PIASy in mice. We show that PIASy is the only member
of the PIAS family that interacts with FIP200, demonstrating
the specificity of this interaction and suggesting that physio-
logical consequences of this interaction may not be compen-
sated for by other PIAS proteins. The present study thus re-
veals a physical interaction between PIASy and FIP200 that
requires the RING domain of PIASy but is independent of any
SUMO ligase activity of PIASy on FIP200 itself. Our in vivo
and in vitro binding assays suggest that PIASy associates with
FIP200 via its C-terminal 1350-to-1591-aa region. Interest-
ingly, this C-terminal domain has been shown to mediate the
interaction of FIP200 with several binding partners involved in
signal transduction such as Pyk2, FAK (41), and ASK1 (11) or
with Listeria monocytogenes ActA protein (27). Notably, the
FIP200 C-terminal region was found to function like full-
length FIP200 in inhibiting Pyk2 kinase activity in vitro and in
blocking Pyk2-induced apoptosis (41). Moreover, this domain
acts as a FIP200 dominant negative mutant on ASK1 binding
to reduce JNK activation and increase tumor necrosis factor
alpha-induced apoptosis in MEFs (11). In this context, it will
be interesting to determine whether PIASy interaction affects
the binding of FIP200 with these protein partners and their
downstream functions.
PIASy has an impact on FIP200 localization and function.
The fact that PIASy binds to FIP200 raised the question of the
localization of this interaction. We found that either exogenous
or endogenous PIASy primarily localizes in the nucleus and
that exogenous FIP200 is predominantly found in the cyto-
plasm, whereas endogenous FIP200 is present in both the
cytoplasm and the nucleus. These observations are in accor-
dance with previous studies (4, 16, 26, 40) and consistent with
a role for FIP200 in both compartments. Remarkably, expres-
sion of PIASy led to the translocation of both exogenous and
endogenous FIP200 from the cytoplasm to the nucleus whereas
expression of the SUMO ligase-defective mutant form had no
effect. These data highlight a novel function for PIASy in the
regulation of the nuclear shuttling of proteins. This finding was
further supported by the observation that the level of the
nuclear fraction of FIP200 was considerably lower in PIASy/
MEFs than in wild-type MEFs. Other studies have implicated
PIAS proteins in the relocalization of proteins in a manner that
is independent from their SUMO ligase activity against such
particular proteins. Notably, PIAS1 binding to the Msx1 ho-
meoprotein is required for appropriate localization of Msx1 in
proximity to target genes at the nuclear periphery, thus leading
to transcriptional repression (23). In this case, neither the
SUMO ligase activity of PIAS1 nor sumoylation of Msx1 is
required for proper localization of Msx1. Another example is
PIASy, which was shown to recruit the transcription factor
LEF1 into nuclear bodies, correlating with repression of LEF1
activity (30). This situation slightly differs from the case of
Msx1 in that, if sequestration of LEF1 in nuclear bodies is
independent from sumoylation of LEF1 per se, it requires the
integrity of the RING domain of PIASy. The requirement for
this domain can be explained by the fact that, as in the case of
FIP200, it mediates the interaction with LEF1 whereas muta-
tion in the RING domain of PIAS1 does not abrogate its
binding to Msx1. Though FIP200 did not appear to undergo
sumoylation in our experiments, the requirement for the
RING domain of PIASy for the interaction and subcellular
localization of FIP200 raises the question of a possible role for
the SUMO pathway in these processes.
Protein-protein interactions are critical for many signaling
processes, including that of the TSC/mTOR signaling cascade,
which plays an essential role in the regulation of cell growth.
The tumor suppressor TSC1 and TSC2 proteins form a het-
erodimer which integrates signals derived from growth factors,
nutrient level, energy status, and hypoxia into a common
growth regulatory signal to the mTOR complex. The TSC1/
TSC2 complex functions as a potent negative regulator of cell
growth, mainly through inhibition of mTOR and its down-
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stream targets S6K and 4E-BP1, which play major roles in cell
size and protein synthesis (14, 22, 29). FIP200 has been shown
to associate with and negatively regulate TSC function, result-
ing in up-regulation of S6K phosphorylation and an increase in
cell size (6, 10, 11). Interestingly, we show that PIASy-FIP200
physical interaction has an impact on FIP200 function. PIASy
can displace FIP200 from the TSC1/TSC2 complex, possibly
through depletion in the cytoplasmic fraction of FIP200, re-
sulting in the restoration of the repressive effect of this com-
plex on S6K phosphorylation. These data thus suggest an as-
yet-unappreciated role of PIASy in S6K activation, and further
studies are necessary to determine the possible contribution of
PIASy to the TSC-mTOR pathway.
FIP200 has an impact on PIASy transcriptional activity.
Having shown that PIASy reduces the cytoplasmic activity of
FIP200, likely by inducing its nuclear transport, we sought to
investigate a possible functional interaction of FIP200 with
PIASy within the nucleus. PIASy has been shown to promote
the sumoylation of p53 and the transcriptional activation of
p53 target genes involved in senescence arrest, such as the gene
for p21 (2). The finding that PIASy plays an important role in
p21 promoter activation is strengthened by the observation
that the p21 protein level fails to be induced by oncogenic Ras
in PIASy/ MEFs, correlating with a delay in the onset of
Ras-induced cellular senescence in these cells (2). FIP200 has
been shown to inhibit G1-S-phase progression by interacting
with and stabilizing p53, leading to an increase in the levels of
the downstream target p21 (26). FIP200 was therefore a plau-
sible candidate coregulator of PIASy for p21 promoter activity.
We show here that PIASy and FIP200 functionally cooperate
to activate the p21 promoter. In contrast, the E3 SUMO ligase-
inactive form of PIASy had no effect on FIP200-induced p21
activation in this assay (data not shown), consistent with the
requirement for a functional interaction between PIASy and
FIP200 for efficient induction of p21 promoter activity. The
notion that FIP200 appears to be a critical cofactor with PIASy
in the transcriptional activation of p21 is underscored by our
observation that acute ablation of FIP200 considerably re-
duced PIASy-induced p21 activation. Furthermore, the finding
that PIASy and FIP200 are corecruited together with p53 to
the endogenous p21 promoter is consistent with a coordinated
regulation of p21 gene expression by these proteins. One pos-
sibility is that FIP200 stabilizes the recruitment of PIASy onto
the p21 promoter, which would, in turn, activate p53 through
sumoylation. Indeed, SUMO-modified p53 has been shown to
behave as a potent activator of the p21 promoter (13). More-
over, the corecruitment of FIP200 and PIASy on the
GADD45 promoter suggests that FIP200 and PIASy might
be involved in the coregulation of several p53-responsive genes
involved in cell cycle arrest. Finally, since FIP200 was shown to
increase Rb mRNA and protein levels (3) and PIASy was
shown to act as a strong corepressor of Rb on E2F target genes
(2), we therefore asked whether FIP200 could exert a core-
pressing effect, along with PIASy, on the E2F-responsive cyclin
E promoter. The repression of the cyclin E promoter mediated
by PIASy was not influenced by the presence of FIP200 (data
not shown), indicating that FIP200 does not act as a general
cofactor with PIASy in regulating gene transcription but rather
acts in a more specific way.
In summary, this study identified FIP200 as a novel inter-
acting partner of PIASy and highlighted an unanticipated role
for PIASy in the cytonuclear shuttling of FIP200. We showed
that this interaction is important for both S6K-associated sig-
nal transduction activities of FIP200 and transcriptional regu-
lation by PIASy, revealing the existence of a close interplay
between PIASy and FIP200, in part mediated by spatial con-
trol. Several lines of evidence have indicated a potential role
for both FIP200 and PIASy in tumor suppression (2, 5, 26).
Future studies, including the use of mouse models condition-
ally inactivated for FIP200 and PIASy, should help in clarifying
the nature of the functional interaction between FIP200 and
PIASy and its potential role in tumor suppression in vivo.
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